DUAL-PATHWAY BLOCKADE THERAPY OFFERS HOPE FOR RARE, HARD-TO-TREAT GYNAECOLOGICAL CLEAR CELL CANCERS
PRNewsWire
·
2026-04-23
·
via The Tech Buzz - Press Releases
International study demonstrates promising clinical activity of pembrolizumab plus lenvatinib in recurrent disease, addressing a longstanding treatment gap SINGAPORE, April 23, 2026 /PRNewswire/ -- Be
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。
